

Cite this: *Chem. Sci.*, 2022, 13, 10057

All publication charges for this article have been paid for by the Royal Society of Chemistry

# An N...H...N low-barrier hydrogen bond preorganizes the catalytic site of aspartate aminotransferase to facilitate the second half-reaction†

Victoria N. Drago,<sup>ab</sup> Steven Dajnowicz,<sup>ab</sup> Jerry M. Parks,<sup>c</sup> Matthew P. Blakeley,<sup>d</sup> David A. Keen,<sup>e</sup> Nicolas Coquelle,<sup>d</sup> Kevin L. Weiss,<sup>b</sup> Oksana Gerlits,<sup>f</sup> Andrey Kovalevsky<sup>g</sup> and Timothy C. Mueser<sup>h</sup>

Pyridoxal 5'-phosphate (PLP)-dependent enzymes have been extensively studied for their ability to fine-tune PLP cofactor electronics to promote a wide array of chemistries. Neutron crystallography offers a straightforward approach to studying the electronic states of PLP and the electrostatics of enzyme active sites, responsible for the reaction specificities, by enabling direct visualization of hydrogen atom positions. Here we report a room-temperature joint X-ray/neutron structure of aspartate aminotransferase (AAT) with pyridoxamine 5'-phosphate (PMP), the cofactor product of the first half reaction catalyzed by the enzyme. Between PMP N<sub>SB</sub> and catalytic Lys258 N $\zeta$  amino groups an equally shared deuterium is observed in an apparent low-barrier hydrogen bond (LBHB). Density functional theory calculations were performed to provide further evidence of this LBHB interaction. The structural arrangement and the juxtaposition of PMP and Lys258, facilitated by the LBHB, suggests active site preorganization for the incoming ketoacid substrate that initiates the second half-reaction.

Received 22nd April 2022  
Accepted 20th July 2022

DOI: 10.1039/d2sc02285k

rsc.li/chemical-science

## Introduction

The family of enzymes utilizing biologically active phosphorylated derivatives of vitamin B<sub>6</sub>, pyridoxal 5'-phosphate (PLP) and pyridoxamine 5'-phosphate (PMP), have long been studied for their chemical diversity. A genomic study of PLP-dependent enzymes revealed that ~4% of all classified activities can be attributed to this ubiquitous family of enzymes, which include transamination,  $\beta$ - and  $\gamma$ -elimination, decarboxylation, phosphorylation, aldol cleavage, racemization, and replacement reactions.<sup>1,2</sup> Owing to their involvement in amino acid metabolism and synthesis of amino acid derivatives, many PLP-dependent enzymes have been identified as potential drug

targets.<sup>3</sup> Detailed understanding of PLP-facilitated catalysis has therefore become necessary for specific inhibitor design.

PLP-dependent enzymes are unified by the conserved active site lysine and the formation of internal and substrate-bound external aldimine structures (Fig. 1a). From the external aldimine onward, the reaction specificity arises. How PLP-mediated catalysis is achieved is governed by two primary concepts. Bond cleavage in PLP-dependent enzymes is promoted by the arrangement of the scissile bond perpendicular to the conjugated system of PLP, known as the Dunathan hypothesis.<sup>4</sup> The PLP resonance then acts as an electron sink to withdraw electrons from the scissile bond into the pyridine ring to stabilize intermediates and promote bond cleavage and rearrangements.<sup>5</sup> These basic concepts explain how PLP can promote catalysis, but they do not describe the diversity of PLP-dependent enzyme activity. Selective protonation of the PLP cofactor directed by the active site environment is considered the most likely explanation for how PLP-dependent enzymes promote specific chemistries.<sup>6</sup> Hence, PLP-dependent catalysis and the enzyme specificities cannot be thoroughly described without knowing the positions of hydrogen atoms that determine the protonation states in the active sites. As a means of directly visualizing hydrogen (and deuterium) positions within a protein, neutron diffraction has proven to be an invaluable technique for our exploration of PLP-driven catalysis.<sup>7</sup>

<sup>a</sup>Department of Chemistry and Biochemistry, University of Toledo, Toledo, OH 43606, USA. E-mail: timothy.mueser@utoledo.edu

<sup>b</sup>Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA. E-mail: kovalevsky@ornl.gov


<sup>c</sup>Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA

<sup>d</sup>Large Scale Structures Group, Institut Laue-Langevin, 71 Avenue des Martyrs, 38000 Grenoble, France

<sup>e</sup>ISIS Facility, Rutherford Appleton Laboratory, Harwell Campus, Didcot, OX11 0QX, UK

<sup>f</sup>Department of Natural Sciences, Tennessee Wesleyan University, Athens, TN 37303, USA

† Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2sc02285k>



**Fig. 1** (a) Chemical structures of pyridoxal 5'-phosphate, internal aldimine, external aldimine, and pyridoxamine 5'-phosphate. Atom labels are given on PMP. (b) AAT half-reactions. AAT facilitates the conversion of PLP and L-aspartate to oxaloacetate and PMP. The PMP form of the cofactor has reactivity toward ketoacids, converting  $\alpha$ -ketoglutarate to glutamate.

Neutron diffraction is a non-destructive technique that allows for the direct observation of hydrogen, H, (or deuterium, D) positions in a protein because the coherent neutron scattering cross-sections of H and D are comparable to those of C, N and O. Unlike X-ray diffraction, which requires ultra-high resolution data to visualize hydrogens, H and D positions are visible in neutron scattering length (or nuclear) maps even at moderate resolutions of  $\sim 2.5$  Å.<sup>8,9</sup> Moreover, cold neutrons with the wavelengths  $> 2$  Å normally used in macromolecular neutron crystallography experiments do not cause radiation damage to protein crystals; thus, radiation damage-free structures can be obtained at near-physiological, ambient temperature. Knowledge of protonation states gained from neutron diffraction is vital in understanding catalysis and ligand binding, can be used to gain further information on protein dynamics, and can help generate accurate starting models for quantum chemical calculations.<sup>10–14</sup> Visualization of protonation states is essential for understanding the electronic modulation of PLP, which is necessary to discern enzymatic mechanisms.

Aspartate aminotransferase (AAT), a model system for fold type I PLP-dependent enzymes, is a biological homodimer that catalyzes the reversible conversion between aspartate and oxaloacetate, and  $\alpha$ -ketoglutarate and glutamate in an ordered, sequential (ping-pong) mechanism (Fig. 1b).<sup>15</sup> In the first half-reaction, substrate aspartate reacts with the internal aldimine to free catalytic Lys258 to produce the external aldimine through a gem-diamine intermediate, setting the stage for a series of proton transfers between substrate-conjugated PLP and Lys258 that ultimately result in the generation of intermediate products PMP and oxaloacetate. In the second, less well-studied half-reaction, PMP facilitates conversion of  $\alpha$ -

ketoglutarate to glutamate going backward along the reaction path described above to regenerate the internal aldimine.

The AAT monomer is described as having a large, fixed domain and a small, flexible domain. The physiological assembly of AAT is a homodimer with the intermonomer contacts primarily between the large domains. The first segment of the N-terminal residues tethers the two domains and the next segment contacts the C-terminal region to form the small flexible domain. The active site residues are positioned between the small and large domains (Fig. 2a). The small domain undergoes conformational change upon substrate binding, switching between the substrate-free internal aldimine open-state to the substrate-bound external aldimine closed-state. The open conformation allows the incoming substrate to bind as a Michaelis complex, inducing a hydrophobic patch of residues to close over the active site (Fig. 2b). In the crystal structures of AAT, crystal packing holds the small domain of one monomer (chain B in Fig. 2a) open, providing a unique opportunity to view the active sites in two different forms.<sup>16,17</sup> Thus, we have exploited the uniqueness of AAT crystal packing to study the enzyme's catalytic mechanism using neutron crystallography. We previously obtained a neutron structure that contained both internal and external aldimines after the reaction with  $\alpha$ -methylaspartate substrate analogue because it reacts only with the PLP located in the monomer capable of the open-close conformational change in the crystal (chain A in Fig. 2a).<sup>17</sup> We thus directly determined the protonation states of the PLP in both the internal and external aldimine states, which were similar to those previously obtained using NMR.<sup>18,19</sup>

Here we describe a 2.2 Å joint X-ray/neutron (XN) structure of AAT in which we captured the stable pyridoxamine 5'-phosphate (PMP), the product of the first half-reaction. By directly






Fig. 2 (a) Overview of AAT homodimer with domain labels (PDB 5VJZ). Chain A (large domain in green) is shown with the small domain in the open (yellow) and closed (orange) conformations. Both positions of the small domain are shown to demonstrate the movement of the active site cap. Chain A (large domain in cyan), which has crystal contacts preventing the closure of the active site cap, is depicted with the small domain in an open (yellow) conformation. (b) Zoomed-in views of the active site opening with external (top) and internal (bottom) aldimines bound. The internal aldimine state adopts an open conformation. The external aldimine becomes closed off by hydrophobic residues in the active site cap.

observing D atoms in the AAT-PMP complex, we determined the protonation states of the chemical groups on the PMP and active site residues specifically indicated with question marks in Fig. 3a that are of particular interest for mapping the enzyme's catalytic mechanism, allowing visualization of hydrogen bonding interactions in the active site. To generate the AAT-PMP complex, we used a crystal in which  $\alpha$ -methylaspartate is already bound in the active site of chain A.<sup>17</sup> This crystal was treated with a solution of *L*-cysteinesulfinic acid (CSA) which, instead of displacing the 2-methylaspartate in chain A, reacted with the internal aldimine PLP located in the “locked open” active site of chain B and the reaction proceeded all the way to PMP. In the normal aspartate reaction, the Schiff base nitrogen

(N<sub>SB</sub>) of the internal or external aldimines becomes the primary amine of PMP when oxaloacetate is released by hydrolysis. When CSA reacts, deamination releases an unstable product,  $\beta$ -sulfinylpyruvate, which hydrolyzes to pyruvate and sulfite, thereby abrogating the reverse reaction (Fig. 3b).<sup>20</sup> The PMP nitrogen rotates to the *si* face, forming a close hydrogen bond with the  $\zeta$ -amine of Lys-258. Nuclear density maps revealed the presence of a potential low-barrier hydrogen bond (LBHB) between the amino groups of the catalytic Lys258 and PMP. To our knowledge, this is the first time an N $\cdots$ H $\cdots$ N LBHB has been experimentally detected in any protein structure, with H observed as D in the joint XN structure. Quantum chemical calculations on a cluster model derived from the neutron




Fig. 3 (a) 2D schematic of PMP in the active site of AAT. The protonation states of atoms designated with question marks are of particular importance in understanding how the active site of AAT modulates the electronics of PLP/PMP. (b) Proposed mechanism for the formation of stable PMP in AAT. As a substrate of AAT, CSA can proceed through transamination in the first half-reaction normally. The product of the reaction,  $\beta$ -sulfinylpyruvate, spontaneously degrades to pyruvate and sulfite, leaving PMP in the active site.



structure provided additional evidence for the LBHB. Our neutron structure contributes to the overall understanding of the reaction mechanism of AAT by mapping exact locations of hydrogen atoms in the AAT active site at the stage of the first half-reaction product.

## Results and discussion

### Joint XN structure

Room-temperature neutron diffraction data to 2.2 Å resolution were collected from a crystal of AAT in complex with PMP. Joint XN refinement was performed using the 1.7 Å room-temperature X-ray data collected from the same crystal to solve the structure and discern the protonation states of the PMP, Lys258 and surrounding ionizable residues (Fig. 3a and Table S1†). Deuterated AAT was purified and crystallized in hydrogenated solvents and the crystal was H/D exchanged by vapor diffusion prior to data collection. Importantly, we have not been able to co-crystallize AAT with substrate analogues, resorting instead to crystal soaking to obtain the AAT-PMP neutron structure. In the AAT crystal, the crystal packing holds the small domain of one chain (chain B) in the homodimer in an open position, resulting in the two active sites possessing different *in crystallo* activities. In the oxidative catabolism of cysteine, the intermediary cysteine sulfinic acid (CSA) may undergo deamination by AAT (Fig. 3b). This reaction yields β-sulfinylpyruvate, which rapidly degrades to sulfite and pyruvate. In an isolated reaction, the CSA substrate can be utilized to form a stable PMP-bound AAT. In this study, we reused the crystal that was previously reacted with α-methylaspartate to exhibit the external aldimine in chain A and

internal aldimine in chain B. By soaking this crystal with CSA, reaction in chain B converted the internal aldimine entirely to PMP, the final product of the first half-reaction even though the chain is locked open. For chain A, two scenarios are possible: (1) CSA displaces α-methylaspartate forming PMP or (2) no reaction with CSA occurs because the small domain is already in the closed conformation. Interestingly, CSA partially reacts with the external aldimine producing uninterpretable mixed electron and nuclear density maps. As a result, the active site in chain A will not be further discussed.

One hypothesis for understanding PLP-dependent catalysis suggests that the PLP cofactor is electronically modulated through selective protonation driven by the active site environment. Therefore, knowledge of the hydrogen atom positions on the cofactor, the active site residues, and hydrogen atom movements during catalysis are critically important for fully understanding PLP-dependent enzymes. In the AAT-PMP neutron structure, we observed no nuclear density peak on the phenolic oxygen O3' of PMP (see Fig. 1 for atom labels), indicating a deprotonated, negatively charged, state. The charge on the deprotonated O3' is stabilized by the partial C–O double bond character provided through electron resonance with the pyridine ring and additionally by two hydrogen bonding interactions with Tyr225 and Asn194 side chains. The pyridine N1 nitrogen of PMP is found in the protonated, positively charged state, having a positive nuclear density peak for a D atom near N1 (Fig. 4a). Protonation of N1 is proposed to increase the charge delocalization by resonance. The same charge-separated state of PLP was observed in the internal and external aldimines.<sup>17</sup> Thus, this aromatic part of PLP remains a zwitterion starting from the reactant (internal aldimine) and through the




Fig. 4 (a) Active site view from a neutron structure of PMP-bound AAT. The  $2|f_o| - |f_c|$  neutron scattering length density map is depicted by grey mesh. Omit  $|f_o| - |f_c|$  difference neutron scattering length density map (magenta mesh) is shown for PMP, Lys258, and Tyr225. Some water molecules present in the active site are omitted for clarity. (b) A positive neutron density peak on C4' is indicative of the transfer of a deuteron from the substrate Cα on the *re* face to the C4' on the *si* face, providing direct evidence for the reaction of CSA in the active site of AAT. The appearance of a distinct neutron density peak favoring one side of C4' suggests there is stereoselectivity to the 1,3-proton transfer. (c) Low-barrier hydrogen bond in the AAT active site revealed by the equidistant neutron density peak between PMP-NSB and Lys258-Nζ. H atoms are colored grey and (D) atoms are colored green.





product (PMP). The hydrogen-bonding network consisting of Asp222, His143, and His189 connects PLP N1 to the bulk solvent and has been shown to influence cofactor electrophilicity. In AAT-PMP, His143 is singly protonated on N $\epsilon$ 2, and thus neutral, whereas His189 is doubly protonated and thus positively charged. In the internal aldimine, His189 is singly protonated on N $\epsilon$ 2,<sup>17</sup> whereas same protonation states for these two histidine residues were observed in the external aldimine as in AAT-PMP. Hence, no protons were transferred to or from the bulk solvent for the reaction to proceed beyond the external aldimine. A singly protonated His193 located near His189 is locked in hydrogen bonding interactions with Ser136 and Thr196 and maintains its protonation state throughout the reaction. A direct visualization of the 1,3-proton shift is present in this new structure. A positive nuclear density peak was observed next to the aminomethyl C4' of PMP, indicating that one of its hydrogens is a deuterium, *i.e.*, C4' is in fact a -C(H)D group (Fig. 4b). In this crystal, the protein is deuterated, the PLP cofactor is hydrogenated, and the C4' is not an exchangeable site. Detection of a D atom on C4' can be readily explained as follows. The proton on the substrate C $\alpha$  is first abstracted by the Lys258 amino group, leading to the formation of a quinonoid intermediate whose lifetime is long enough for H/D exchange to occur. Subsequently, a D atom is delivered to the C4' position by the protonated Lys258. Therefore, the 1,3-proton transfer through the *si* face stereochemical movement predicted by Dunathan<sup>4,21</sup> and facilitated by Lys258 has occurred.

In the AAT-PMP neutron structure the amine N<sub>SB</sub> of PMP is positioned 2.8 Å away from the Lys258 amine N $\zeta$ , indicating a hydrogen bond. The nuclear density map revealed a D atom located halfway between the two amino nitrogens (Fig. 4c). Therefore, this hydrogen bond can potentially be a low-barrier hydrogen bond (LBHB). LBHBs are a type of short hydrogen bonds characterized by a delocalized proton shared equally by the two hydrogen bond acceptor atoms. In an LBHB, the zero-point vibrational frequency of the shared proton is close to or greater than the potential energy barrier, allowing the proton to move freely between the donor and acceptor atoms with the

average position in the center.<sup>22–24</sup> Although LBHBs have previously been found in the neutron structures of various enzymes, including an N $\cdots$ H $\cdots$ O LBHB detected in the external aldimine of AAT between the substrate carboxylate oxygen and N<sub>SB</sub> atoms,<sup>17,25,26</sup> an N $\cdots$ H $\cdots$ N LBHB has not been observed previously. However, we note that in a neutron structure of cholesterol oxidase enzyme a short hydrogen bond between the main chain amide nitrogen of Gly residue and a flavin cofactor nitrogen was characterized as having an elongated amide N–H bond.<sup>27</sup> The aminomethyl group of PMP in the AAT-PMP neutron structure is not coplanar with the pyridine, with the C4'–N<sub>SB</sub> bond rotated by 78° above the plane of pyridine (*si* face) to allow for the formation of the hydrogen bond with Lys258 (Fig. 5). The conformation of PMP in the active site, facilitated by the interaction with Lys258, is similar to that of the internal aldimine, which adopts a C3–C4–C4'–N<sub>SB</sub> torsion angle of 46° for the Schiff base. Conversely, in the external aldimine the C4'–N<sub>SB</sub> bond is moved below the pyridine plane (*re* face) possibly to avoid clash with the freed Lys258. LBHBs, with a high covalent character, are known to be stronger than conventional hydrogen bonds.<sup>28</sup> As the aminomethyl group is free to rotate around the single C4–C4' bond and PMP–N<sub>SB</sub> serves as a primary amine to react with ketoacids, the formation of a strong N $\cdots$ H $\cdots$ N LBHB would ensure a proper positioning of the PMP amine for the subsequent attack on the carbonyl of  $\alpha$ -ketoglutarate, facilitating catalysis along the second half-reaction.

### Quantum chemical calculations

To provide further evidence that an LBHB is likely formed between PMP and Lys258 we performed density functional theory (DFT) calculations at the SMD/ $\omega$ B97XD/Def2-SVP level of theory using a 151-atom cluster model derived from the neutron structure of AAT-PMP. Importantly, protonation states of the AAT amino acid residues and the PMP were kept as observed in the neutron structure, with the D atoms reverted to H. We placed the LBHB proton on the Lys258 amine, referred to as the reactant state, or on the PMP amine, referred to as the product state, and performed geometry optimizations of the two




Fig. 5 C3–C4–C4'–N<sub>SB</sub> torsion angles for (a) internal aldimine (PDB 5VJZ), (b) external aldimine (PDB 5VJZ), and (c) PMP. In both the internal aldimine and PMP, N<sub>SB</sub> is on the *si* face with C3–C4–C4'–N<sub>SB</sub> torsion angles of 46° and 78°, respectively. In the external aldimine N<sub>SB</sub> is on the *re* face with a C3–C4–C4'–N<sub>SB</sub> torsion angle of –28°. Active site preorganization holds the incoming substrate on the *re* face between Arg292 and Arg386 while Lys258 is held in the internal aldimine on the *si* face. When the substrate displaces Lys258 to form the external aldimine, the C3–C4–C4'–N<sub>SB</sub> torsion rotates so that N<sub>SB</sub> is on the *re* face. N<sub>SB</sub> returns to the *si* face upon formation of PMP and product release, suggesting that the active site is at a resting state when N<sub>SB</sub> is on the *si* face whereas N<sub>SB</sub> on the *re* face is active.



stationary points. The product state was found to be  $+0.9 \text{ kcal mol}^{-1}$  higher in energy than the reactant. Thus, protonated PMP is slightly less stable than protonated Lys258 in the simplified cluster model of AAT (Fig. 6a). Next, we generated a potential energy profile for the proton transfer from the reactant to the product state. The calculated potential energy barrier heights for the forward and reverse proton transfers were very low at  $1.5 \text{ kcal mol}^{-1}$  for proton transfer from PMP to Lys258 and  $0.6 \text{ kcal mol}^{-1}$  for the reverse proton transfer. We emphasize that the calculations were performed at 0 K, with no zero-point energy corrections applied, and H nuclei were treated as classical, not quantum, particles. Therefore, the results should be considered as qualitative for comparison with the neutron structure in which the nuclei were observed directly from the experiment. At 300 K, the thermal energy  $kT$  would increase the energies of the reactant and product states relative to the transition state by  $\sim 0.6 \text{ kcal mol}^{-1}$ , lowering the proton transfer barrier accordingly and indicating possible formation of an LBHB. In the DFT calculation the  $\text{N}\cdots\text{N}$  separation is  $2.7 \text{ \AA}$  in both the reactant and product states, and  $2.6 \text{ \AA}$  in the transition state where H is located at the midpoint between the N atoms. The distances are close to the  $2.8 \text{ \AA}$   $\text{N}\cdots\text{N}$  distance

observed in the joint XN structure (Table S2†). Although the  $\text{N}\cdots\text{N}$  separation appears shorter in the DFT calculations and may indicate an H/D isotopic effect leading to the  $\text{N}\cdots\text{N}$  distance elongation in the joint XN structure, as was shown by NMR studies on small molecules,<sup>29–31</sup> the difference of  $0.1\text{--}0.2 \text{ \AA}$  is negligible. The reason is that the atomic position error for the heavy atoms in AAT-PMP complex based on the X-ray data is  $0.17 \text{ \AA}$ , about the same as the  $\text{N}\cdots\text{N}$  distance elongation. Thus, potential geometric H/D isotopic effects are not resolved within the margin of error in the joint XN structure. In the reactant and product states the respective amines are protonated ammonium ions ( $-\text{NH}_3^+$ ). Natural population analysis (NPA) partial charges revealed that the partial charge of the shared proton is largely unaffected by its position in the hydrogen bond, with partial charges of  $+0.49$ ,  $+0.47$ , and  $+0.47$  in the reactant, transition state, and product, respectively (Fig. 6b). This result suggests that the proton is delocalized and that the hydrogen bond is also assisted by charge. In addition, considering the role of nuclear quantum effects such as zero-point motion, we conclude that the  $\text{N}\cdots\text{H}\cdots\text{N}$  hydrogen bond observed in the AAT-PMP neutron structure can be classified both as an LBHB and as a charge-assisted hydrogen bond.<sup>32,33</sup>




Fig. 6 (a) Potential energy curve for proton transfer between Lys258- $\text{N}_\zeta$  and PMP- $\text{N}_{\delta\text{B}}$ . Energies are given in  $\text{kcal mol}^{-1}$  and are reported relative to the Lys258-protonated (reactant) structure. The for the reactant and product are designated with a blue dot. The transition state (‡) energy obtained from the optimized structure is indicated by a red dot. (b) Natural population partial charge analysis of the Lys258- $\text{N}_\zeta$ -protonated state, transition state, and PMP- $\text{N}_{\delta\text{B}}$ -protonated state. Atoms are color coded by partial charge (red = negative, black = neutral, green = positive) and the partial charges of Lys258- $\text{N}_\zeta$ , PMP- $\text{N}_{\delta\text{B}}$ , and the shared proton are labeled. The partial charge of the shared proton is unaffected by its position in the hydrogen bond.




Fig. 7 Proposed mechanism for the first half-reaction of AAT based on observations from neutron structures. Protons depicted in red were directly visualized by neutron diffraction. The substrate  $\text{C}_\alpha$ -substrate proton (blue) was depicted with stereochemistry to indicate the removal from the *re* face by Lys258 and protonation  $\text{C}_4'$  on the *si* face.



## Conclusion

Together with our previous neutron structures of AAT,<sup>17</sup> we have now mapped out the positions of hydrogen atoms in the internal aldimine, external aldimine, and PMP, the three major intermediate states along the AAT-catalyzed transamination reaction pathway.<sup>3,15,34</sup> Neutron diffraction has thus afforded us the opportunity to further clarify the mechanism of the first half-reaction in which Asp is converted to oxaloacetate (Fig. 7). As found in the internal and external aldimines, the PMP pyridine N1 is protonated and the PMP phenolic O3' is deprotonated in the AAT-PMP neutron structure. A nuclear density peak on C4' provides evidence of the fundamental 1,3-proton transfer in which the catalytic Lys258 facilitates proton abstraction from the substrate C $\alpha$  and its subsequent placement on C4'. PMP-N<sub>SB</sub> and Lys258-N $\zeta$  are primary amines locked in an apparent LBHB, orienting N<sub>SB</sub> on the *si* face of the active site above the plane of the PMP pyridine ring, ready to attack the carbonyl of an incoming  $\alpha$ -ketoglutarate, which signifies the start of the second half-reaction. The LBHB appears to be important for catalysis as it preorganizes the active site for the incoming substrate preventing the highly dynamic aminomethyl group of PMP and the side chain of Lys258 from freely rotating in the active site cavity. DFT calculations provided evidence that an N $\cdots$ H $\cdots$ N LBHB is formed between PMP-N<sub>SB</sub> to Lys258-N $\zeta$ , in agreement with the observed position of the hydrogen atom in the AAT-PMP neutron structure.

## Materials and methods

### Deuteration, purification and crystallization of AAT

*E. coli* T7 Express LacIQ cells carrying the gene for AAT were grown in deuterated minimal media prepared using hydrogenous glycerol and 99.8% D<sub>2</sub>O as described in detail previously.<sup>2,17,35</sup> Overexpression of deuterated AAT was achieved in a BIOFLO 310 (Eppendorf) bioreactor, growing cells at 30 °C to an OD<sub>600</sub> of 10.0. The cells were induced with 1 mM isopropyl  $\beta$ -D-thiogalactopyranoside at 20 °C and fed glycerol for 24 h. Purification was carried out as previously described using Ni-NTA affinity chromatography.<sup>35</sup> The deuterated AAT crystal was grown in 40 mM NaOAc (pH 5.4), 2 mM PLP, 9% polyethylene glycol (PEG) 6000, and 10% glycerol using batch method crystallization. The PMP form of the cofactor was obtained by soaking the crystal with 50 mM Tris-HCl (pH 7.5), 5% PEG 6000, 5% glycerol, and 300 mM L-cysteinesulfinate in D<sub>2</sub>O for 24 h. The soaking was performed by directly adding liquid to the quartz capillary containing the crystal.

### Neutron diffraction data collection

Neutron quasi-Laue diffraction data from a 0.65 mm<sup>3</sup> crystal of the AAT-PMP complex were collected at room temperature using the LADI-III diffractometer<sup>36</sup> at the Institut Laue-Langevin (ILL) in Grenoble. A neutron wavelength range ( $\Delta\lambda/\lambda \sim 30\%$ ) of 3.10–4.15 Å was used for data collection with diffraction data extending to 2.2 Å resolution. The crystal was held stationary at different  $\phi$  (vertical rotation axis) for each exposure. A total of 32

images were recorded with an exposure time of 18 hours per image from 4 different crystal orientations. The neutron data were processed using the Daresbury Laboratory LAUE suite program *LAUEGEN* modified to account for the cylindrical geometry of the detector.<sup>37,38</sup> The program *LSCALE*<sup>39</sup> was used to determine the wavelength-normalization curve using the intensities of symmetry-equivalent reflections measured at different wavelengths. No explicit absorption corrections were applied. The data were merged and scaled using *SCALA*.<sup>40</sup> Neutron data collection can be found in Table S1.†

### Room temperature X-ray diffraction data collection and structure refinement

After neutron diffraction data collection, room temperature X-ray diffraction data were collected on the same deuterated AAT crystal on beamline FIP-BM30A at the European Synchrotron Radiation Facility (ESRF) in Grenoble. X-ray diffraction data were integrated with XDS and reduced and scaled using XSCALE of the XDS program suite.<sup>41</sup> The structure was refined against the room temperature X-ray diffraction data in Phenix<sup>42</sup> to produce an input model for joint XN refinement. X-ray data collection statistics are shown in Table S1.†

### Joint X-ray/neutron (XN) refinement

Joint X/N refinement was carried out with the patch, nCNS,<sup>43</sup> in the structure solution program, CNS<sup>44,45</sup> using room temperature X-ray and neutron diffraction data. Following a single rigid body refinement, rounds of atomic position, individual atomic displacement, and occupancy refinements were performed with manual adjustments made to the structure in Coot.<sup>46</sup> Joint XN refinement statistics are given in Table S1.† Based on the D incorporation into C–H bonds during protein expression and H/D exchange with D<sub>2</sub>O estimated using refined D atom occupancies, AAT is  $\sim 85\%$  deuterated.

### Quantum chemical calculations

A 151-atom cluster model was generated from the neutron crystal structure of AAT-PMP consisting of ten active site residues (Tyr70, Thr109, Trp140, N194, Asp222, Tyr225, Ser255, Ser257, Lys258, and Arg266), PMP, and two crystallographic waters (ESI Fig. S1†). The residues were truncated, and the free valences on terminal carbons were saturated with hydrogens. The terminal carbons were constrained to their crystallographic positions for all residues, as well as the oxygen positions of the two crystallographic waters. Tyr225, Tyr70, and Trp140 required additional atoms to be constrained to prevent internal rotations during the geometry optimizations.

Geometry optimizations were performed at the SMD<sup>47</sup>/ $\omega$ B97XD/Def2-SVP<sup>48,49</sup> level of theory. Zero-point energies and other thermodynamic corrections were not included because the geometric constraints led to inaccuracies in the vibrational frequencies. A dielectric constant of 4.0 was used for the SMD solvent model to mimic the surrounding enzyme environment. The  $\omega$ B97XD density functional approximation was chosen for its ability to describe hydrogen bonding interactions and barrier heights accurately.<sup>50</sup> Vibrational frequency calculations



were used to confirm energy minima and transition states. All calculations were performed with Gaussian 16.<sup>51</sup> A rigid potential energy scan was used to map the potential energy pathway for the proton transfer between Lys258-N $\zeta$  and PMP-N<sub>SB</sub>. Ten steps were taken with a step size of 0.1 Å. The resulting profile provided an initial guess for the transition state, which was subsequently used to perform a transition state optimization. Natural population analysis (NPA) charges of the stationary points were calculated with the NBO program in Gaussian16.<sup>52</sup>

## Data availability

The structure and corresponding structure factors have been deposited into the protein data bank with the PDB accession code 7TUR. ESI† is available online.

## Author contributions

SD, AK and TCM designed the study. VND and SD expressed and purified the protein. VND, SD and K LW performed protein deuteration. SD and AK crystallized the protein and generated the complex. NC collected X-ray data and VND refined the structure. VND and JMP performed DFT calculations. DAK, OG and MPB collected, reduced and analyzed neutron diffraction data. VND and AK performed joint X-ray/neutron structure refinement. VND, AK and TCM wrote original draft, and all authors edited and reviewed the paper.

## Conflicts of interest

There are no conflicts of interest to declare.

## Acknowledgements

This research used resources at the Spallation Neutron Source and the High Flux Isotope Reactor, which are DOE Office of Science User Facilities operated by the Oak Ridge National Laboratory. The Office of Biological and Environmental Research supported research at ORNL's Center for Structural Molecular Biology (CSMB), a DOE Office of Science User Facility. ORNL is managed by UT-Battelle LLC for DOE's Office of Science, the single largest supporter of basic research in the physical sciences in the United States. The authors thank the Institut Laue Langevin (beamline LADI-DALI) for awarded neutron beamtime. This work was also supported by the National Institute of General Medical Sciences (NIGMS), the National Institutes of Health (NIH), grant number R01GM137008-01A1.

## Notes and references

- 1 R. Percudani and A. Peracchi, *EMBO Rep.*, 2003, **4**, 850–854.
- 2 T. C. Mueser, V. Drago, A. Kovalevsky and S. Dajnowicz, *Methods Enzymol.*, 2020, **634**, 333–359.
- 3 A. C. Eliot and J. F. Kirsch, *Annu. Rev. Biochem.*, 2004, **73**, 383–415.

- 4 H. C. Dunathan, *Proc. Natl. Acad. Sci. U. S. A.*, 1966, **55**, 712–716.
- 5 J. P. Richard, T. L. Amyes, J. Crueiras and A. Rios, *Curr. Opin. Chem. Biol.*, 2009, **13**, 475–483.
- 6 M. D. Toney, *Biochim. Biophys. Acta*, 2011, **1814**, 1407–1418.
- 7 M. P. Blakeley and A. D. Podjarny, *Emerging Top. Life Sci.*, 2018, **2**, 39–55.
- 8 D. W. Kneller, G. Phillips, K. L. Weiss, S. Pant, Q. Zhang, H. M. O'Neill, L. Coates and A. Kovalevsky, *J. Biol. Chem.*, 2020, **295**, 17365–17373.
- 9 O. Gerlits, K. L. Weiss, M. P. Blakeley, G. Veglia, S. S. Taylor and A. Kovalevsky, *Sci. Adv.*, 2019, **5**, eaav0482.
- 10 N. Niimura, M. Takimoto-Kamimura and I. Tanaka, *Encyclopedia of analytical chemistry: applications, theory and instrumentation*, 2006, pp. 1–30.
- 11 O. Gerlits, T. Wymore, A. Das, C. H. Shen, J. M. Parks, J. C. Smith, K. L. Weiss, D. A. Keen, M. P. Blakeley, J. M. Louis, P. Langan, I. T. Weber and A. Kovalevsky, *Angew. Chem., Int. Ed. Engl.*, 2016, **55**, 4924–4927.
- 12 D. W. Kneller, G. Phillips, K. L. Weiss, Q. Zhang, L. Coates and A. Kovalevsky, *J. Med. Chem.*, 2021, **64**, 4991–5000.
- 13 L. Gajdos, M. P. Blakeley, M. Haertlein, V. T. Forsyth, J. M. Devos and A. Imbert, *Nat. Commun.*, 2022, **13**, 194.
- 14 K. Koruza, B. P. Mahon, M. P. Blakeley, A. Ostermann, T. E. Schrader, R. McKenna, W. Knecht and S. Z. Fisher, *J. Struct. Biol.*, 2019, **205**, 147–154.
- 15 M. D. Toney, *Arch. Biochem. Biophys.*, 2014, **544**, 119–127.
- 16 S. Rhee, M. M. Silva, C. C. Hyde, P. H. Rogers, C. M. Metzler, D. E. Metzler and A. Arnone, *J. Biol. Chem.*, 1997, **272**, 17293–17302.
- 17 S. Dajnowicz, R. C. Johnston, J. M. Parks, M. P. Blakeley, D. A. Keen, K. L. Weiss, O. Gerlits, A. Kovalevsky and T. C. Mueser, *Nat. Commun.*, 2017, **8**, 955.
- 18 H. H. Limbach, M. Chan-Huot, S. Sharif, P. M. Tolstoy, I. G. Shenderovich, G. S. Denisov and M. D. Toney, *Biochim. Biophys. Acta*, 2011, **1814**, 1426–1437.
- 19 M. Chan-Huot, A. Dos, R. Zander, S. Sharif, P. M. Tolstoy, S. Compton, E. Fogle, M. D. Toney, I. Shenderovich, G. S. Denisov and H.-H. Limbach, *J. Am. Chem. Soc.*, 2013, **135**, 18160–18175.
- 20 N. C. Furumo and J. F. Kirsch, *Arch. Biochem. Biophys.*, 1995, **319**, 49–54.
- 21 H. C. Dunathan, *Vitam. Horm.*, 1970, **28**, 399–414.
- 22 J. A. Gerlt, M. M. Kreevoy, W. Cleland and P. A. Frey, *Chem. Biol.*, 1997, **4**, 259–267.
- 23 B. Schiott, B. B. Iversen, G. K. Madsen, F. K. Larsen and T. C. Bruice, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 12799–12802.
- 24 W. W. Cleland, *Arch. Biochem. Biophys.*, 2000, **382**, 1–5.
- 25 P. Kumar, P. K. Agarwal and M. J. Cuneo, *ChemBioChem*, 2021, **22**, 288–297.
- 26 O. Gerlits, D. A. Keen, M. P. Blakeley, J. M. Louis, I. T. Weber and A. Kovalevsky, *J. Med. Chem.*, 2017, **60**, 2018–2025.
- 27 E. Golden, L. J. Yu, F. Meilleur, M. P. Blakeley, A. P. Duff, A. Karton and A. Vrielink, *Sci. Rep.*, 2017, **7**, 40517.
- 28 S. J. Grabowski, *Chem. Rev.*, 2011, **111**, 2597–2625.





- 29 S. N. Smirnov, N. S. Golubev, G. S. Denisov, H. Benedict, P. Schah-Mohammed and H.-H. Limbach, *J. Am. Chem. Soc.*, 1996, **118**, 4094–4101.
- 30 H. Benedict, H.-H. Limbach, M. Wehlan, W.-P. Fehlhammer, N. S. Golubev and R. Janoschek, *J. Am. Chem. Soc.*, 1998, **120**, 2939–2950.
- 31 H.-H. Limbach, P. M. Tolstoy, N. Pérez-Hernández, J. Guo, I. G. Shenderovich and G. S. Denisov, *Isr. J. Chem.*, 2009, **49**, 199–216.
- 32 A. Cahlik, J. Hellerstedt, J. I. Mendieta-Moreno, M. Švec, V. M. Santhini, S. Pascal, D. Soler-Polo, S. I. Erlingsson, K. Výborný, P. Mutombo, O. Marsalek, O. Siri and P. Jelinek, *ACS Nano*, 2021, **15**, 10357–10365.
- 33 S. J. Grabowski, *Annu. Rep. Prog. Chem., Sect. C: Phys. Chem.*, 2006, **102**, 131–165.
- 34 P. Christen and P. K. Mehta, *Chem. Rec.*, 2001, **1**, 436–447.
- 35 S. Dajnowicz, J. M. Parks, X. Hu, K. Gesler, A. Y. Kovalevsky and T. C. Mueser, *J. Biol. Chem.*, 2017, **292**, 5970–5980.
- 36 M. P. Blakeley, S. C. Teixeira, I. Petit-Haertlein, I. Hazemann, A. Mitschler, M. Haertlein, E. Howard and A. D. Podjarny, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 1198–1205.
- 37 J. Campbell, *J. Appl. Crystallogr.*, 1995, **28**, 228–236.
- 38 J. W. Campbell, Q. Hao, M. M. Harding, N. D. Nguti and C. Wilkinson, *J. Appl. Crystallogr.*, 1998, **31**, 496–502.
- 39 S. Arzt, J. W. Campbell, M. M. Harding, Q. Hao and J. R. Helliwell, *J. Appl. Crystallogr.*, 1999, **32**, 554–562.
- 40 M. Weiss, *J. Appl. Crystallogr.*, 2001, **34**, 130–135.
- 41 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 125–132.
- 42 D. Liebschner, P. V. Afonine, N. W. Moriarty, P. Langan and P. D. Adams, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2018, **74**, 800–813.
- 43 M. Mustyakimov and P. Langan, *C-06, 104 Patch for CNS: nCNS. An open source distribution patch for CNS for macromolecular structure refinement, Los Alamos National Security, Los Alamos, NM, USA*, 2007.
- 44 A. T. Brunger, P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson and G. L. Warren, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 1998, **54**, 905–921.
- 45 P. D. Adams, M. Mustyakimov, P. V. Afonine and P. Langan, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2009, **65**, 567–573.
- 46 P. Emsley and K. Cowtan, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2004, **60**, 2126–2132.
- 47 A. V. Marenich, C. J. Cramer and D. G. Truhlar, *J. Phys. Chem. B*, 2009, **113**, 6378–6396.
- 48 F. Weigend, *Phys. Chem. Chem. Phys.*, 2006, **8**, 1057–1065.
- 49 F. Weigend and R. Ahlrichs, *Phys. Chem. Chem. Phys.*, 2005, **7**, 3297–3305.
- 50 N. Mardirossian and M. Head-Gordon, *Mol. Phys.*, 2017, **115**, 2315–2372.
- 51 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery Jr, J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman and D. J. Fox, *Gaussian 16, Revision A.03*, Gaussian Inc., Wallingford, CT, 2016.
- 52 A. E. Reed, R. B. Weinstock and F. Weinhold, *J. Chem. Phys.*, 1985, **83**, 735–746.

